Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer
Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer
Shorter, Simpler Consent Form Proposed For Phase I Trials
How Much Is Life Worth? The $440 Billion Question
Sunitinib Prolongs Survival In Poor Prognosis, Study Finds
Breast MRI Recipients More Likely To Choose Mastectomy
Opioid Pain Reliever Approved With Risk Reduction Plan
NCI Cooperative Group Clinical Trials Approved
Trending Stories
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt - As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.”